
IONIS PHARMACEUTICALS INC
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Ionis Pharmaceuticals develops RNA-targeted therapeutics based on antisense oligonucleotide technology to treat diseases including neurological, cardiovascular, and rare genetic disorders, both independently and through partnerships with other pharmaceutical companies.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Devers Shannon L.EVP, Chief Human Resources Ofc | Sell | $59K | 1,357at $43.54 | Oct 16, 2026 |
| Swayze EricEVP Research | Sell | $2K | 53at $43.54 | Oct 16, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable IONS activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.